hVIVO plc Award of Deferred Bonus Share Options (4846F)

TIDMHVO

RNS Number : 4846F

hVIVO plc

18 May 2017

For immediate release 7.00am: 18 May 2017

HVIVO PLC

("hVIVO" or the "Company")

Award of Deferred Bonus Share Options

hVIVO plc (AIM: HVO), a specialty biopharma company with clinical testing capabilities, announces that on 17 May 2017 it awarded the following options over ordinary shares of 5.0 pence each in the Company to persons discharging managerial responsibilities ("PDMR"):

 
 PDMR             Total no. of shares   Type of awards 
                   under award 
---------------  --------------------  --------------- 
 Kym Denny        32,813                Deferred Bonus 
                                         Award 
---------------  --------------------  --------------- 
 Graham Yeatman   26,250                Deferred Bonus 
                                         Award 
---------------  --------------------  --------------- 
 

The deferred bonus share options will normally vest on the second anniversary of date of grant (17 May 2019), subject to continued employment but no other performance condition. The deferred bonus awards represent 50% of 2016 bonus awarded by the Remuneration Committee, with the other 50% paid as cash.

The exercise price payable per share is the nominal price of a share (currently 5 pence). Vested options will be able to be exercised up to the tenth anniversary of date of grant.

Details of the full notifications received by the Company are set out below:

 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
---  ------------------------------------------------------------------------ 
 a)   Name                             Kym Denny and Graham Yeatman 
---  -------------------------------  --------------------------------------- 
 2    Reason for Notification 
---  ------------------------------------------------------------------------ 
 a)   Position/status                  Chief Executive Officer and 
                                        Chief Financial & Business 
                                        Officer 
---  -------------------------------  --------------------------------------- 
 b)   Initial notification/Amendment   Initial notification 
---  -------------------------------  --------------------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  ------------------------------------------------------------------------ 
 a)   Name                             hVIVO PLC 
---  -------------------------------  --------------------------------------- 
 b)   Legal Entity Identifier          2138003PFXHA22YPN676 
---  -------------------------------  --------------------------------------- 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ------------------------------------------------------------------------ 
 a)   Description of                   Ordinary shares of 5 pence 
       the financial instrument,        each 
       type of instrument 
 
       Identification                   GB00B6ZM0X53 
       code 
---  -------------------------------  --------------------------------------- 
 b)   Nature of the transaction        Grant of deferred bonus share 
                                        options as follows: 
 
                                        The deferred bonus share options 
                                        will normally vest on the 
                                        second anniversary of date 
                                        of grant (17 May 2019), subject 
                                        to continued employment but 
                                        no other performance condition. 
 
                                        The exercise price payable 
                                        per share is the nominal price 
                                        of a share (currently 5 pence). 
 
                                        Vested options will be able 
                                        to be exercised up to the 
                                        tenth anniversary of date 
                                        of grant. 
---  -------------------------------  --------------------------------------- 
 c)   Currency                         GBP 
---  -------------------------------  --------------------------------------- 
 d)   Price(s) and volume(s)            Director          Price (p)   Volume 
                                        ----------------  ----------  ------- 
                                         Kym Denny         5.0         32,813 
                                        ----------------  ----------  ------- 
                                         Graham Yeatman    5.0         26,250 
                                        ----------------  ----------  ------- 
---  -------------------------------  --------------------------------------- 
 e)        Aggregated information 
             *    Aggregated volume      59,063 shares 
                                         5.0 pence 
 
             *    Price 
---  -------------------------------  --------------------------------------- 
 f)   Date of the transaction          17 May 2017 
---  -------------------------------  --------------------------------------- 
 g)   Place of the transaction         Outside a trading venue 
---  -------------------------------  --------------------------------------- 
 

For further information please contact:

 
 hVIVO plc                            [phone] 
 Kym Denny (Chief Executive 
  Officer) 
 Graham Yeatman (Chief Financial 
  & Business Officer) 
 
 Numis Securities Limited              [phone] 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
 James Black / Michael Burke 
  (Corporate Broking) 
 
 FTI Consulting 
 Simon Conway / Victoria Foster 
  Mitchell (UK)                       [phone] 
 John Capodanno / Evan Smith 
  (US)                                [phone] 
 

Notes to Editors:

hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2000 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHDDGDUUGBBGRR

(END) Dow Jones Newswires

May 18, 2017 02:01 ET (06:01 GMT)